0000950170-23-010746.txt : 20230330 0000950170-23-010746.hdr.sgml : 20230330 20230330070051 ACCESSION NUMBER: 0000950170-23-010746 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230330 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230330 DATE AS OF CHANGE: 20230330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGEN CORP CENTRAL INDEX KEY: 0000711377 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 382367843 STATE OF INCORPORATION: MI FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17988 FILM NUMBER: 23777120 BUSINESS ADDRESS: STREET 1: 620 LESHER PLACE CITY: LANSING STATE: MI ZIP: 48912 BUSINESS PHONE: 5173729200 MAIL ADDRESS: STREET 1: 620 LESHER PLACE CITY: LANSING STATE: MI ZIP: 48912 8-K 1 neog-20230330.htm 8-K 8-K
falseNEOGEN CORP000071137700007113772023-03-302023-03-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 30, 2023

 

NEOGEN CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Michigan

0-17988

38-2367843

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

620 Lesher Place Lansing, Michigan

48912

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code 517-372-9200

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

 

Title of each Class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

 

Common Stock, $0.16 par value per share

NEOG

NASDAQ Global Select Market

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition

On March 30, 2023, Neogen Corporation issued a press release announcing results of operations for its fiscal 2023 third quarter and nine months ended February 28, 2023. A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits

(d)
Exhibits

 

 

 

99.1

Press Release dated March 30, 2023

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

NEOGEN CORPORATION

 

 

 

 

(Registrant)

 

 

 

 

Date: March 30, 2023

 

 

/s/ David H. Naemura

 

 

 

 

David H. Naemura

 

 

 

Chief Financial Officer

 

 EX-99 2 neog-ex99_1.htm EX-99.1 EX-99

 

Exhibit 99.1

Neogen Announces Third-Quarter 2023 Results

•
Revenue of $218.3 million, an increase of 70% over the prior-year quarter.
•
Net income of $8.2 million; $0.04 per diluted share.
•
Adjusted Net Income of $26.5 million; $0.12 per diluted share.
•
Adjusted EBITDA of $51.3 million, a margin of 23.5%.

 

LANSING, Mich., March 30, 2023 – Neogen Corporation (NASDAQ: NEOG) announced today the results of the third quarter ended February 28, 2023.

“The breadth of our product portfolio contributed to both legacy Neogen segments delivering quarterly core growth in a weaker end market environment,” said John Adent, Neogen’s President and Chief Executive Officer. “The performance of the former 3M Food Safety Division was mixed, with market demand offset by the production backlog situation at our transition manufacturing partner, where we believe significant engagement from senior levels of their organization and a modified reporting structure provide a path to successful resolution. Despite navigating what we expect to be a transitory issue, market reception to the merger has been positive and we are focused on positioning the combined business for long-term success. We have a growing pipeline of targeted synergy opportunities and recently opened our new distribution center in Mount Sterling, Kentucky, which will be a single, more-efficient point of distribution in the U.S. for the entire company. We also continued to add critical personnel, with additions to our back-office and ancillary teams, who will play a key role in supporting our larger enterprise.”

Adent continued, “We are excited about the opportunities we have ahead of us as the clear, pure-play leader in the food security market, with a portfolio consisting of over 95% consumable products. While our market is not immune to economic slowdowns, it historically has been resilient and has what we believe are long-term, secular tailwinds – heightened pathogen awareness, the growing prevalence of food allergies and increasingly health-conscious consumers who demand to know what’s in their food. There is clearly work that remains ahead of us, but I’m proud of the progress we’ve made and the efforts of our team members globally as we integrate a high-quality business and lay the groundwork for One Neogen moving forward.”

Financial and Business Highlights

Revenues for the third quarter were $218.3 million, an increase of 70.2% compared to $128.2 million in the prior year. Core revenue growth, which excludes the impacts of foreign currency translation and acquisitions completed in the last 12 months, was 4.0%, while acquisitions contributed 68.1%. Foreign currency was a headwind of 1.9%. International sales, which accounted for 49.6% of total company revenue, grew 8.9% on a core basis.

The third quarter marked the 123rd of the past 129 quarters that Neogen reported revenue increases compared to the same quarter in the prior year.

Net income for the third quarter was $8.2 million, or $0.04 per diluted share, compared to $5.4 million, or $0.05 per diluted share, in the prior-year period. The increase in net income was driven primarily by incremental revenues from the former 3M Food Safety Division, which generated margins higher than the legacy company average margin. This increase was partially offset by transaction and integration costs, interest expense and the amortization of acquisition-related intangibles, all related to the recently completed merger with the former 3M Food Safety Division. Adjusted Net Income was $26.5 million, or $0.12 per diluted share, compared to $16.2 million, or $0.15 per diluted share, in the prior-year period. Higher Adjusted EBITDA drove the increase in Adjusted Net Income, more than offsetting the increase in interest expense. On a per-share basis, Adjusted Net Income was lower by $0.03 in the third quarter compared to the prior-year period, a result of the increase in shares outstanding related to the 3M Food Safety transaction.

Gross margin, expressed as a percentage of sales, was 49.5% in the third quarter of fiscal 2023. This compares to a gross margin of 44.8% in the same quarter a year ago, with the increase primarily due to the higher gross margins generated by the incremental revenues from the former 3M Food Safety Division.

Third-quarter Adjusted EBITDA was $51.3 million, representing an Adjusted EBITDA Margin of 23.5%, compared to $24.9 million and a margin of 19.4% in the prior year. The margin expansion was primarily driven by the increase in gross margin, which more than offset expenses added during the quarter to accommodate the expanded scale of the business.

Food Safety Segment

Revenues for the Food Safety segment were $151.5 million in the third quarter, an increase of 141.5% compared to $62.8 million in the prior year, consisting of 5.8% core growth, 139.1% from acquisitions, and a foreign currency headwind of 3.4%. The core growth was led by the Culture Media & Other category, which benefited from a large order from a vaccine manufacturer. In the Bacterial & General Sanitation product category, a solid increase in sales of Soleris® spoilage detection products was partially offset by a decline in sales of AccuPoint® general sanitation products, due in part to supply challenges, resulting in modest core growth. The Natural Toxins, Allergens, & Drug Residues category experienced a slight core revenue decline, with increases in sales of aflatoxin test kits offset by a decline in sales of allergen test kits, due in part to supply challenges, and the discontinuation of a drug residue product line consisting of test kits for international dairy markets.

Animal Safety Segment

Revenues for the Animal Safety segment were $66.7 million in the third quarter, an increase of 1.9%, compared to $65.5 million in the prior year’s third quarter, consisting of 2.2% core growth and a foreign currency headwind of 0.3%. The core growth was led by the Company’s portfolio of biosecurity products, driven largely by insect control share gains in the animal protein market. The core growth in biosecurity products was partially offset by core revenue declines in Veterinary Instruments & Disposables, due to a difficult comparison to new business won in the prior year, and in Animal Care & Other, due to lower sales of antibiotics and vitamin injectables.

The Company’s worldwide genomics business performed well in the quarter, with core growth of 7.7%, led by volume increases in the global beef markets, partially offset by declines in testing in China caused by a continuation of COVID-related lab closures.

Liquidity and Capital Resources

As of February 28, 2023, the Company had total cash and investments of $183.2 million and total outstanding debt of $900.0 million, which reflects a repayment of $40.0 million in the quarter, as well as committed borrowing headroom of $150.0 million.

Conference Call and Webcast

Neogen Corporation will host a conference call today at 8:00 a.m. Eastern Time to discuss the Company’s financial results. The live webcast of the conference call and accompanying presentation materials can be accessed through Neogen’s website at neogen.com/investor-relations. For those unable to access the webcast, the conference call can be accessed by dialing 1.844.757.5681 (U.S.) or 1.412.317.5297 (International) and requesting the Neogen Corporation Third Quarter FY23 Earnings Call (Conference ID: 10176510). A replay of the conference call and webcast will be available shortly following the conclusion of the call, and can be accessed domestically or internationally by dialing 1.877.344.7529 or 1.412.317.0088, respectively, and providing the entry code 6598643, or through Neogen’s Investor Relations website at neogen.com/investor-relations.

About Neogen

Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to “Every day, protect the people and animals we care about.” The Company’s Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen’s Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the company’s most recently filed Form 10-K.

NEOGEN CORPORATION

UNAUDITED CONSOLIDATED STATEMENT OF INCOME (LOSS)

(In thousands, except for per share)

 

 

 

Three Months Ended February 28,

 

 

Nine Months Ended February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Food Safety

 

$

151,542

 

 

$

62,756

 

 

$

377,528

 

 

$

192,610

 

Animal Safety

 

 

66,713

 

 

 

65,488

 

 

 

203,109

 

 

 

194,456

 

Total revenue

 

 

218,255

 

 

 

128,244

 

 

 

580,637

 

 

 

387,066

 

Cost of revenues

 

 

110,291

 

 

 

70,832

 

 

 

297,864

 

 

 

209,052

 

Gross margin

 

 

107,964

 

 

 

57,412

 

 

 

282,773

 

 

 

178,014

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Sales & marketing

 

 

38,598

 

 

 

21,477

 

 

 

98,329

 

 

 

63,220

 

Administrative

 

 

46,424

 

 

 

24,997

 

 

 

151,369

 

 

 

60,985

 

Research & development

 

 

7,258

 

 

 

4,561

 

 

 

18,985

 

 

 

13,218

 

Total operating expenses

 

 

92,280

 

 

 

51,035

 

 

 

268,683

 

 

 

137,423

 

Operating income

 

 

15,684

 

 

 

6,377

 

 

 

14,090

 

 

 

40,591

 

Other (expense) income

 

 

(17,944

)

 

 

266

 

 

 

(43,782

)

 

 

707

 

(Loss) income before tax

 

 

(2,260

)

 

 

6,643

 

 

 

(29,692

)

 

 

41,298

 

Income tax

 

 

(10,450

)

 

 

1,200

 

 

 

(1,250

)

 

 

7,950

 

Net income (loss)

 

$

8,190

 

 

$

5,443

 

 

$

(28,442

)

 

$

33,348

 

Net income (loss) per diluted share

 

$

0.04

 

 

$

0.05

 

 

$

(0.16

)

 

$

0.31

 

Shares to calculate per share amount

 

 

216,399

 

 

 

108,133

 

 

 

179,666

 

 

 

108,130

 

 

NEOGEN CORPORATION

UNAUDITED SUMMARIZED CONSOLIDATED BALANCE SHEET DATA

(In thousands)

 

 

 

February 28, 2023

 

 

May 31, 2022

 

Assets

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash & investments

 

$

183,214

 

 

$

381,051

 

Accounts receivable

 

 

146,393

 

 

 

99,674

 

Inventories

 

 

143,863

 

 

 

122,313

 

Other current assets

 

 

81,901

 

 

 

23,760

 

Total current assets

 

 

555,371

 

 

 

626,798

 

Property & equipment, net

 

 

164,888

 

 

 

110,584

 

Goodwill & other assets

 

 

3,788,505

 

 

 

255,547

 

Total assets

 

$

4,508,764

 

 

$

992,929

 

Liabilities & Equity

 

 

 

 

 

 

Current liabilities

 

$

107,155

 

 

$

77,844

 

Non-current liabilities

 

 

1,276,054

 

 

 

27,711

 

Equity: Shares outstanding, 216,221 at February 28, 2023 & 107,801 at May 31, 2022

 

 

3,125,555

 

 

 

887,374

 

Total liabilities & equity

 

$

4,508,764

 

 

$

992,929

 

 

Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures, which management believes are useful to investors, securities analysts and other interested parties. Management uses Adjusted EBITDA as a key profitability measure. This is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business either period-over-period or with other businesses. Adjusted EBITDA Margin is Adjusted EBITDA for a particular period expressed as a percentage of revenues for that period.

Management uses Adjusted Net Income as an additional measure of profitability. Adjusted Net Income is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Core revenue growth is a non-GAAP measure that represents net sales for the period excluding the impacts of foreign currency translation rates and the first-year impacts of acquisitions and disposals, where applicable. We present core revenue growth because it allows for a meaningful comparison of year-over-year performance without the volatility caused by foreign currency gains or losses, or the incomparability that would be caused by the impact of an acquisition or disposal.

These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please see below for a reconciliation of historical non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP.

NEOGEN CORPORATION

RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

(In thousands, except for percentages)

 

 

 

Three Months Ended February 28,

 

 

Nine Months Ended February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net income (loss)

 

$

8,190

 

 

$

5,443

 

 

$

(28,442

)

 

$

33,348

 

Provision for income taxes

 

 

(10,450

)

 

 

1,200

 

 

 

(1,250

)

 

 

7,950

 

Depreciation and amortization

 

 

27,471

 

 

 

6,322

 

 

 

59,938

 

 

 

17,833

 

Interest expense (income), net

 

 

16,820

 

 

 

(314

)

 

 

35,844

 

 

 

(741

)

EBITDA

 

$

42,031

 

 

$

12,651

 

 

$

66,090

 

 

$

58,390

 

Share-based compensation

 

 

2,812

 

 

 

1,607

 

 

 

7,311

 

 

 

5,045

 

FX transaction loss (gain) on loan revaluation(1)

 

 

(697

)

 

 

—

 

 

 

5,092

 

 

 

—

 

Certain transaction fees and integration costs

 

 

2,890

 

 

 

10,595

 

 

 

55,754

 

 

 

19,908

 

Contingent consideration adjustments

 

 

(300

)

 

 

—

 

 

 

(300

)

 

 

—

 

Loss on sale of minority interest

 

 

1,516

 

 

 

—

 

 

 

1,516

 

 

 

—

 

Impairment and scrap of discontinued product line(2)

 

 

3,633

 

 

 

—

 

 

 

3,633

 

 

 

—

 

Inventory step-up charge

 

 

(614

)

 

 

—

 

 

 

3,245

 

 

 

—

 

Adjusted EBITDA

 

$

51,271

 

 

$

24,853

 

 

$

142,341

 

 

$

83,343

 

Adjusted EBITDA margin (% of sales)

 

 

23.5

%

 

 

19.4

%

 

 

24.5

%

 

 

21.5

%

Adjusted EBITDA increase

 

 

106.3

%

 

 

 

 

 

70.8

%

 

 

 

 

(1)
Net foreign currency transaction (gain) loss associated with the revaluation of non-functional currency intercompany loans established in connection with 3M Food Safety transaction
(2)
Expenses associated with goodwill and intangible impairments and inventory scrap amounts related to certain discontinued product lines

NEOGEN CORPORATION

RECONCILIATION OF NET INCOME TO ADJUSTED NET INCOME

(In thousands, except for per share)

 

 

 

Three Months Ended February 28,

 

 

Nine Months Ended February 28,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net income (loss)

 

$

8,190

 

 

$

5,443

 

 

$

(28,442

)

 

$

33,348

 

Amort of acquisition-related intangibles

 

 

22,680

 

 

 

1,977

 

 

 

46,637

 

 

 

5,432

 

Share-based compensation

 

 

2,812

 

 

 

1,607

 

 

 

7,311

 

 

 

5,045

 

FX transaction loss (gain) on loan revaluation(1)

 

 

(697

)

 

 

—

 

 

 

5,092

 

 

 

—

 

Certain transaction fees and integration costs

 

 

2,890

 

 

 

10,595

 

 

 

55,754

 

 

 

19,908

 

Contingent consideration adjustments

 

 

(300

)

 

 

—

 

 

 

(300

)

 

 

—

 

Loss on sale of minority interest

 

 

1,516

 

 

 

—

 

 

 

1,516

 

 

 

—

 

Impairment and scrap of discontinued product line(2)

 

 

3,633

 

 

 

—

 

 

 

3,633

 

 

 

—

 

Inventory step-up charge

 

 

(614

)

 

 

—

 

 

 

3,245

 

 

 

—

 

Other adjustments(3)

 

 

1,514

 

 

 

—

 

 

 

5,864

 

 

 

—

 

Estimated tax effect of above adjustments(4)

 

 

(15,095

)

 

 

(3,385

)

 

 

(24,864

)

 

 

(6,873

)

Adjusted Net Income

 

$

26,529

 

 

$

16,237

 

 

$

75,446

 

 

$

56,860

 

Adjusted Earnings per Share

 

$

0.12

 

 

$

0.15

 

 

$

0.42

 

 

$

0.53

 

 

(1)
Net foreign currency transaction (gain) loss associated with the revaluation of non-functional currency intercompany loans established in connection with 3M Food Safety transaction
(2)
Expenses associated with goodwill and intangible impairments and inventory scrap amounts related to certain discontinued product lines
(3)
Income tax benefit associated with non-deductible transaction costs that were recognized as expenses in prior periods
(4)
Tax effect of adjustments is calculated using projected effective tax rates for each applicable item

Source: Neogen Corporation

Contact

Bill Waelke

(517) 372-9200

ir@neogen.com

EX-101.LAB 3 neog-20230330_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Amendment Flag Amendment Flag Entity Incorporation State Country Code Entity Incorporation State Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre Commencement Tender Offer Pre Commencement Tender Offer Security 12b Title Security 12b Title Entity Address, State or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Security Exchange Name Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Cover [Abstract] Cover [Abstract] Trading Symbol Trading Symbol EX-101.SCH 4 neog-20230330.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 neog-20230330_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Mar. 30, 2023
Cover [Abstract]  
Entity Registrant Name NEOGEN CORP
Amendment Flag false
Entity Central Index Key 0000711377
Document Type 8-K
Document Period End Date Mar. 30, 2023
Entity Incorporation State Country Code MI
Entity File Number 0-17988
Entity Tax Identification Number 38-2367843
Entity Address, Address Line One 620 Lesher Place
Entity Address, City or Town Lansing
Entity Address, State or Province MI
Entity Address, Postal Zip Code 48912
City Area Code 517
Local Phone Number 372-9200
Security 12b Title Common Stock, $0.16 par value per share
Trading Symbol NEOG
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 7 neog-20230330_htm.xml IDEA: XBRL DOCUMENT 0000711377 2023-03-30 2023-03-30 false NEOGEN CORP 0000711377 8-K 2023-03-30 MI 0-17988 38-2367843 620 Lesher Place Lansing MI 48912 517 372-9200 Common Stock, $0.16 par value per share NEOG NASDAQ false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !@X?E8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 8.'Y6$+<>JNX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.FV 0]3U N($$A*30-PBQ]LBFB9*C-J]/6W9.B%X (ZQ_WS^ M++G!J#$D>DXA4F)'^6KT79\UQHTX,$<-D/% WN1R2O132-SP]TQZBP0^S M)ZBEO 5/;*QA S.PB"M1M(U%C8D,AW3"6USQ\3-U"\PB4$>>>LY0E16(=IX8 MCV/7P 4PPYB2S]\%LBMQJ?Z)73H@3LDQNS4U#$,YJ"4W[5#!V]/CR[)NX?K, MID>:?F6G^1AI(\Z37]7=_?9!M+6L52%5H>2VJK24^OKF?7;]X7<1]L&ZG?O' MQF?!MH%?=]%^ 5!+ P04 " 8.'Y6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M !@X?E8HZS$P/ 0 'T0 8 >&PO=V]R:W-H965T&UL MC9A=<^(V%(;_BL;M]"J)+4/X2($90I(ML_EP ^W.M-,+80O0Q+9<28;DW_?( M)C;=-<=P 98MO7Y\CO7JB-%>JC>]Y=R0]R1.]=C9&I/=N*X.MSQA^DIF/(4K M:ZD29J"I-J[.%&=1,2B)7=_S>F["1.I,1L6Y0$U&,C>Q2'F@B,Z3A*F/6Q[+ M_=BASN>)5['9&GO"G8PRMN$+;O[( @4MMU*)1,)3+61*%%^/G2F]N?6[=D#1 MXT_!]_KHF-A'64GY9AOS:.QXEHC'/#16@L'/CL]X'%LEX/CW(.I4][0#CX\_ MU1^*AX>'63'-9S+^)B*S'3L#AT1\S?+8O,K];_SP0-=6+Y2Q+K[)ONS;]1P2 MYMK(Y# 8"!*1EK_L_1"(J*"\8X9-1DKNB;*]0%(]:C 8X MD=JL+(R"JP+&F0:N(GMZH8'P=M2T#\A M^,34%>EX%\3W_,[_A[O 5@'Z%:!?Z'5.Z,WDCBOR]W2EC8(4_M-$5"ITFQ7L M>WVC,Q;RL0,OKN9JQYW)+S_1GOI^#J8^N00LU>^$980(OG,$MY$B>L\ MW[]\N7\FLY?7 *'J5E1=5&T*.8V*O#[$;--$@X]?LUASA..ZXK@^)SHS(%$L MACWT^PA6K\+JH6+56[_\R!ISA0\?7'Y%(/H51/\\ MB( K(>WLBPC,X48>7*F:04ADU MDN+"3W.$;EC1#<^A>Q Q)\]YLN*J"037\"YI?S@8(#34JRW4.X=GR=[)/(*$ MBK4(RY"=IFN1[ PN_4ZO/^ABV:1')D_/(9Q&$1B@OO@\((_0C[RDC8ELD>SY M'GGDL/ H$L1@KAAG[?44M>H?.&>V)159RGWS4H3+/3*H'M(-AE;;/#W+YRNT M+9#:@-G^);*3L[1%L3L84A]CJ_V? MXK9=9' *]>)I%%S@FF*&3VO'I[AG/\H08A)L98J91HM(I^]?#J'@Q8AJ^Z>X M:R]XF"L;'NJOR%*8N#D\N,A,)DGAS3)\NR _>U>T1S*FR([%.2<9S$Z]90J= MG?6B0''S7BH6P70BBX]D)>-&6%S UC@82;T 4-R]J]#=OX=;EF[XR:*K1>AY MNKB;_HZ5J?4JX..6_0V #$^)S4B>'E8 W5BNXD)MM9=?V[Z/>_1"QB(4QN;L M"=Q*"=:8M1:55IZC4A[WXT#Q(CP<[+(LOZ!*A5?T9;UNGHXM>JUDM;O[N!/_ M0#;7.@>R5D!6QEO%DN7/ZZZ>S;"=I M=67=A['-HN6/O.-%Q[ MI#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4 M!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M. MB^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4 M?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_& M?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQ MY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7 M^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJ MOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T% M^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%N MXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI" M5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2 M='@//GL?)=-[*CG_5U/\!%!+ P04 " 8.'Y6EXJ[', 3 @ "P M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6= MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6' MTD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( !@X?E8<.&7J/P$ M #P" / >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0 MJA:5BON2=8C%/B*O RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6 MI;(&;])-;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$ M[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z M,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT, MPS/%ML%PZ&C$179EH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X* M/:XH$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFB MG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6 M<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ &#A^ M5F60>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O M$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1 ML.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3K MU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY8 M4(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F," MJ;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R M]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]> M?P%02P$"% ,4 " 8.'Y6!T%-8H$ "Q $ @ $ M 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( !@X?E80MQZJ[@ "L" M 1 " :\ !D;V-0&UL4$L! A0#% @ &#A^5BCK,3 \! ?1 !@ M ("!#0@ 'AL+W=O7!E&UL4$L%!@ ) - D /@( -\3 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - neog-20230330.htm 8 neog-20230330.htm neog-20230330.xsd neog-20230330_lab.xml neog-20230330_pre.xml neog-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "neog-20230330.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "neog-20230330.htm" ] }, "labelLink": { "local": [ "neog-20230330_lab.xml" ] }, "presentationLink": { "local": [ "neog-20230330_pre.xml" ] }, "schema": { "local": [ "neog-20230330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "neog", "nsuri": "http://www.neogen.com/20230330", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "neog-20230330.htm", "contextRef": "C_506ba04f-261f-488d-9da9-f761f9f47020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "neog-20230330.htm", "contextRef": "C_506ba04f-261f-488d-9da9-f761f9f47020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.neogen.com/20230330/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-010746-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-010746-xbrl.zip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